Helena Tayton-Martin
Fondateur chez ADAPTIMMUNE THERAPEUTICS PLC
Fortune : 318 060 $ au 30/04/2024
Postes actifs de Helena Tayton-Martin
Sociétés | Poste | Début | Fin |
---|---|---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Corporate Officer/Principal | 15/03/2017 | - |
Fondateur | 01/01/2008 | - | |
Directeur des opérations | 01/01/2008 | 15/03/2017 | |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | - | - |
Directeur des opérations | 17/09/2009 | - | |
Fondateur | 01/01/2008 | - | |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | President | - | - |
Secrétaire Général | - | - |
Historique de carrière de Helena Tayton-Martin
Anciens postes connus de Helena Tayton-Martin
Sociétés | Poste | Début | Fin |
---|---|---|---|
TRILLIUM THERAPEUTICS | Directeur/Membre du Conseil | 01/10/2017 | 17/11/2021 |
Independent Dir/Board Member | 01/10/2017 | 17/11/2021 | |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Directeur des opérations | 01/01/2008 | 01/01/2017 |
Fondateur | 01/01/2008 | 01/01/2017 | |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Formation de Helena Tayton-Martin
London Business School | Masters Business Admin |
University of Bristol | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 6 |
Etats-Unis | 3 |
Canada | 2 |
Opérationnelle
Chief Operating Officer | 3 |
Founder | 3 |
Director/Board Member | 2 |
Sectorielle
Health Technology | 5 |
Health Services | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
Entreprise privées | 5 |
---|---|
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |
- Bourse
- Insiders
- Helena Tayton-Martin
- Expérience